Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2018’, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

- The report reviews pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics and enlists all their major and minor projects

- The report assesses Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adverum Biotechnologies Inc

BioCryst Pharmaceuticals Inc

Cevec Pharmaceuticals GmbH

CSL Ltd

iBio Inc

Ionis Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Pharming Group NV

ProMetic Life Sciences ...

Adverum Biotechnologies Inc

BioCryst Pharmaceuticals Inc

Cevec Pharmaceuticals GmbH

CSL Ltd

iBio Inc

Ionis Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Pharming Group NV

ProMetic Life Sciences Inc

Rezolute Inc

Shire Plc

Verseon Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Overview ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Overview

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Companies Involved in Therapeutics Development

Adverum Biotechnologies Inc

BioCryst Pharmaceuticals Inc

Cevec Pharmaceuticals GmbH

CSL Ltd

iBio Inc

Ionis Pharmaceuticals Inc

Kalvista Pharmaceuticals Inc

Pharming Group NV

ProMetic Life Sciences Inc

Rezolute Inc

Shire Plc

Verseon Corp

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drug Profiles

ADVM-053 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATN-035 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATN-249 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCX-7353 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (human) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (human) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (recombinant) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1 esterase inhibitor (recombinant) – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C1-esterase inhibitor – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSL-312 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

icatibant acetate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-PKKLRx – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-PKKRx – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KVD-818 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KVD-900 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KVD-XXX – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lanadelumab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RZ-602 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Plasma Kallikrein for Hereditary Angioedema – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Dormant Projects

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Discontinued Products

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Product Development Milestones

Featured News & Press Releases

May 29, 2018: BioCryst Announces Presentation of Additional Analyses of the APeX-1 Clinical Trial of BCX7353 at the 2018 European Academy of Allergy and Clinical Immunology (EAACI) Congress

May 29, 2018: KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

May 24, 2018: BioCryst's BCX7353 Receives European Regulatory Designations for the Treatment of Hereditary Angioedema

Apr 18, 2018: The Swiss Agency for Therapeutic Products (Swissmedic) Validates Shire's Marketing Authorization Application for Investigational Hereditary Angioedema Treatment Lanadelumab

Mar 29, 2018: Shire Reports Regulatory Milestones for Investigational Hereditary Angioedema Treatment Lanadelumab

Mar 15, 2018: BioCryst Announces Initiation of the Phase 3 APeX-2 Trial of BCX7353 in Patients with Hereditary Angioedema

Mar 15, 2018: CSL Behring Receives Patient Impact Award For Subcutaneous Prophylactic Treatment To Prevent Hereditary Angioedema Attacks

Mar 03, 2018: New Data from Pivotal Phase 3 Study Investigating Lanadelumab as a Prophylactic Treatment for Hereditary Angioedema to be Presented at 2018 AAAAI/WAO Joint Congress

Feb 28, 2018: BioCryst Announces Initiation of the APeX-S Long-Term Safety Trial of BCX7353 in Patients with Hereditary Angioedema

Feb 27, 2018: The European Medicines Agency Grants Accelerated Assessment for Shire's Lanadelumab Being Evaluated for the Prevention of Attacks in Hereditary Angioedema Patients Aged 12 Years and Older

Feb 23, 2018: FDA Accepts Shire Biologics License Application (BLA) and Grants Priority Review for Lanadelumab for the Prevention of Attacks in Hereditary Angioedema (HAE) Patients

Feb 15, 2018: Shire Announces FDA Acceptance of sBLA for CINRYZE (C1 esterase inhibitor [human]) for Pediatric Hereditary Angioedema Use

Feb 13, 2018: Shire Provides Regulatory Progress Update On Lanadelumab

Jan 17, 2018: Pharming announces FDA Acceptance for Review of Supplemental Biologics License Application for RUCONEST for Prophylaxis of Hereditary Angioedema Attacks

Jan 10, 2018: Verseon presents hereditary angioedema program at Biotech Showcase

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2018

Number of Products under Development by ...

List of Tables

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Adverum Biotechnologies Inc, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by BioCryst Pharmaceuticals Inc, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Cevec Pharmaceuticals GmbH, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by CSL Ltd, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by iBio Inc, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Kalvista Pharmaceuticals Inc, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Pharming Group NV, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by ProMetic Life Sciences Inc, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Rezolute Inc, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Shire Plc, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Pipeline by Verseon Corp, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Dormant Projects, H1 2018

Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2018

Number of Products under Development by ...

List of Figures

Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports